Concord Biotech rallies 8% as Kotak upgrades stock to 'add', sees 11% upside

After an impressive 220 bps EBITDA margin expansion in FY24, Concord is guiding for further improvement in FY25/26.

Related Keywords

Rakesh Jhunjhunwala , Ontario Inc , Concord Biotech , Kotak Institutional Equities ,